In March 2025, the company declared new programs for just a direct-to-client presenting of its Wegovy weight loss drug. The company recognized a whole new pharmacy, referred to as NovoCare, which would cost prospects $499 every month for entry to the drug, fewer than 50 % the expense of the drug by way of other pharmaceutical distribution networks.